A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

• Status: Completed
• Trial end date: 2018-10-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate experimental medication BMS-986231 in patients with different levels of kidney function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Body weight ≥ 45 kg and ≤ 120 kg

• BMI ≥ 18 kg/m^2 and ≤ 35 kg/m^2

• Heart rate ≥ 50 bpm and < 95 bpm

• Stable renal impairment, defined as no clinically significant change in disease status, as documented by the subject's most recent eGFR assessment

• No changes in medication within 30 days prior to study drug administration

Exclusion Criteria:

• Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests

• History of chronic headaches, defined as occurring 15 days or more a month, over the previous 3 months

• History of headaches related to caffeine withdrawal

• History of migraine or cluster headaches

• Patients requiring dialysis will not be enrolled in this study

Other protocol defined inclusion/exclusion criteria could apply